Approval Alert | Acalabrutinib Plus Bendamustine/Rituximab in Previously Untreated MCL

“Some of the early data that came out of the [ECHO] trial that led to this approval does suggest that it may be beneficial in some high-risk patients,” Tycel Phillips, MD, said.

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.